Antibody-mediated Cell Depletion Therapies in Multiple Sclerosis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Sep 29

PMID 36172350

Authors

Alice Mariottini

Paolo A Muraro

Jan D Lunemann

Affiliations

Soon will be listed here.

Abstract

Development of disease-modifying therapies including monoclonal antibody (mAb)-based therapeutics for the treatment of multiple sclerosis (MS) has been extremely successful over the past decades. Most of the mAb-based therapies approved for MS deplete immune cell subsets and act through activation of cellular Fc-gamma receptors expressed by cytotoxic lymphocytes and phagocytes, resulting in antibody-dependent cellular cytotoxicity or by initiation of complement-mediated cytotoxicity. The therapeutic goal is to eliminate pathogenic immune cell components and to potentially foster the reconstitution of a new and healthy immune system. Ab-mediated immune cell depletion therapies include the CD52-targeting mAb alemtuzumab, CD20-specific therapeutics, and new Ab-based treatments which are currently being developed and tested in clinical trials. Here, we review recent developments in effector mechanisms and clinical applications of Ab-based cell depletion therapies, compare their immunological and clinical effects with the prototypic immune reconstitution treatment strategy, autologous hematopoietic stem cell transplantation, and discuss their potential to restore immunological tolerance and to achieve durable remission in people with MS.

Citing Articles

Beyond the Stroke: A Case Report of Multiple Sclerosis.

Karri A, Khalid A, Iyer K Cureus. 2024; 16(11):e73962.

PMID: 39703256 PMC: 11658855. DOI: 10.7759/cureus.73962.

Cutting-edge approaches to B-cell depletion in autoimmune diseases.

Robinson W, Fiorentino D, Chung L, Moreland L, Deodhar M, Harler M Front Immunol. 2024; 15:1454747.

PMID: 39445025 PMC: 11497632. DOI: 10.3389/fimmu.2024.1454747.

Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti-CD20 therapy.

Waede M, Voss L, Kingo C, Moeller J, Elkjaer M, Illes Z Ann Clin Transl Neurol. 2024; 11(10):2657-2672.

PMID: 39279291 PMC: 11514931. DOI: 10.1002/acn3.52182.

Dermatological Neoplastic Diseases Complicating Treatment with Monoclonal Antibodies for Multiple Sclerosis.

Bile F, Sparaco M, Ruocco E, Miele G, Maida E, Vele R J Clin Med. 2024; 13(17).

PMID: 39274345 PMC: 11396336. DOI: 10.3390/jcm13175133.

Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy.

Martin S, Guenette M, Oh J Drug Des Devel Ther. 2024; 18:3025-3042.

PMID: 39050801 PMC: 11268567. DOI: 10.2147/DDDT.S388410.

References

Hauser S, Waubant E, Arnold D, Vollmer T, Antel J, Fox R . B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008; 358(7):676-88. DOI: 10.1056/NEJMoa0706383. View

Burt R, Muraro P, Farge D, Oliveira M, Snowden J, Saccardi R . New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis. Bone Marrow Transplant. 2021; 56(7):1509-1517. DOI: 10.1038/s41409-021-01277-y. View

Havrdova E, Arnold D, Cohen J, Hartung H, Fox E, Giovannoni G . Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. Neurology. 2017; 89(11):1107-1116. PMC: 5595278. DOI: 10.1212/WNL.0000000000004313. View

Schuetz C, Hoenig M, Moshous D, Weinstock C, Castelle M, Bendavid M . Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Adv. 2018; 2(19):2550-2553. PMC: 6177653. DOI: 10.1182/bloodadvances.2018020883. View

Jones J, Phuah C, Cox A, Thompson S, Ban M, Shawcross J . IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009; 119(7):2052-61. PMC: 2701868. DOI: 10.1172/JCI37878. View

Gingele S, Jacobus T, Konen F, Hummert M, Suhs K, Schwenkenbecher P . Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients. Cells. 2019; 8(1). PMC: 6356421. DOI: 10.3390/cells8010012. View

Hill-Cawthorne G, Button T, Tuohy O, Jones J, May K, Somerfield J . Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2011; 83(3):298-304. DOI: 10.1136/jnnp-2011-300826. View

Agius M, Klodowska-Duda G, Maciejowski M, Potemkowski A, Li J, Patra K . Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler. 2017; 25(2):235-245. PMC: 6360486. DOI: 10.1177/1352458517740641. View

Gordan S, Albert H, Danzer H, Lux A, Biburger M, Nimmerjahn F . The Immunological Organ Environment Dictates the Molecular and Cellular Pathways of Cytotoxic Antibody Activity. Cell Rep. 2019; 29(10):3033-3046.e4. DOI: 10.1016/j.celrep.2019.10.111. View

10.

Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P . Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014; 81(1):49-60. DOI: 10.1016/j.neuron.2013.10.061. View

11.

George B, Seals S, Aban I . Survival analysis and regression models. J Nucl Cardiol. 2014; 21(4):686-94. PMC: 4111957. DOI: 10.1007/s12350-014-9908-2. View

12.

Moutsianas L, Agarwala V, Fuchsberger C, Flannick J, Rivas M, Gaulton K . The power of gene-based rare variant methods to detect disease-associated variation and test hypotheses about complex disease. PLoS Genet. 2015; 11(4):e1005165. PMC: 4407972. DOI: 10.1371/journal.pgen.1005165. View

13.

Cross A, Stark J, Lauber J, Ramsbottom M, Lyons J . Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006; 180(1-2):63-70. PMC: 1769354. DOI: 10.1016/j.jneuroim.2006.06.029. View

14.

Wattjes M, Rovira A, Miller D, Yousry T, Sormani M, de Stefano M . Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients. Nat Rev Neurol. 2015; 11(10):597-606. DOI: 10.1038/nrneurol.2015.157. View

15.

Kim Y, Kim G, Shin H, Hyun J, Kim S, Lee E . Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis. J Neuroinflammation. 2018; 15(1):300. PMC: 6206644. DOI: 10.1186/s12974-018-1334-y. View

16.

Cohen J, Coles A, Arnold D, Confavreux C, Fox E, Hartung H . Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012; 380(9856):1819-28. DOI: 10.1016/S0140-6736(12)61769-3. View

17.

Rensel M, Zabeti A, Mealy M, Cimbora D, She D, Drappa J . Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial. Mult Scler. 2021; 28(6):925-932. PMC: 9024030. DOI: 10.1177/13524585211047223. View

18.

Cox A, Thompson S, Jones J, Robertson V, Hale G, Waldmann H . Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol. 2005; 35(11):3332-42. DOI: 10.1002/eji.200535075. View

19.

Barton J, Hardy T, Riminton S, Reddel S, Barnett Y, Coles A . Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab. Neurology. 2017; 88(10):1004-1006. DOI: 10.1212/WNL.0000000000003694. View

20.

de Flon P, Gunnarsson M, Laurell K, Soderstrom L, Birgander R, Lindqvist T . Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology. 2016; 87(2):141-7. DOI: 10.1212/WNL.0000000000002832. View